Please login to the form below

Not currently logged in
Email:
Password:

Janssen boosts vaccines pipeline with GlycoVaxyn deal

Research will focus on targeting multiple bacterial pathogens

Janssen has agreed a deal with Swiss vaccines specialist GlycoVaxyn to research and develop a vaccine for multiple bacterial pathogens.

Its early development will see GlycoVaxyn collaborate with Janssen's vaccines- focused affiliate Crucell, but once the programme enters later-stage clinical studies, Janssen will take over development and then lead commercialisation of any product that gains approval.

The partners' research efforts will make use of GlycoVaxyn's bio-conjugation technology, which is designed to support the development of polyvalent conjugate vaccines – a form of vaccine that can be used to protect against multiple targets.

GlycoVaxyn's co-founder and chief scientific officer Michael Wacker said the technology “should make the development and commercialisation of these vaccines more feasible and reliable”.

Financial details of the deal were not disclosed, although GlycoVaxyn will receive an upfront and milestone payments, plus reimbursement of R&D expenses and royalties on future sales.

The announcement comes just weeks after GlycoVaxyn signed another big pharma deal, tying up with GSK to collaborate on the development of anti-bacterial conjugate vaccines.

As with the Janssen deal, financial terms were not disclosed, nor the specific type of infection to be targeted.

The two deals in quick succession demonstrate a wider faith in GlycoVaxyn's bio-conjugate vaccine platform, and the company's CEO Philippe Dro welcomed the latest agreement.

He said: “This collaboration is a further confirmation of the position GlycoVaxyn is about to occupy in the vaccine development space.

“The whole team is dedicated to establish GlycoVaxyn's technology as a powerful platform able to generate innovative vaccine candidates.”

8th January 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...
How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...